Current Activities
Cohort studies
The EuroSIDA Study is a prospective observational cohort study of more than 9.700 patients followed in 72 hospitals in 26 European Countries. The main objective of the study is to assess the impact of antiretroviral drugs on the outcome of the general population of HIV-infected patients living in Europe. The study is sponsored by the European Commission and by unrestricted grants from GlaxoSmithKline, Roche and Boehringer-Ingelheim.
The D:A:D study , Data Collection on Adverse events of Anti-HIV Drugs (D:A:D), is a data collection study for HIV-infected patients under active follow up. 11 cohorts across the world participate and 21.000 patients have been enrolled during the year 2000.
The CoDe Project The goal of this project is to develop a uniform coding system that can be applied widely, including:
· a detailed data collection on causes of death and contributing factors, and
· a centralised review process of the data collected.
The HIV-TB Project. “Co-infection with Mycobacterium tuberculosis among HIV-infected patients in Europe” is a prospective European multi-cohort study. The long-term objective of this project is to describe and analyse the aspects mentioned above and potential regional diversities therein. This will ultimately lead to a better understanding of the clinical management of HIV and TB coinfection as well as any regional diversity in Europe and the underlying reasons.
Coordination of international randomised trials
CHIP takes on the responsibility of coordinating international trials for other scientific groups, where the knowledge and experience of working in the Scandinavian and European countries can contribute and ensure the quick and safe set-up of the trials.
The ESPRIT trial will compare the effects of subcutaneous recombinant interleukin-2 (SC rIL-2) and no SC rIL-2 on disease progression and death over a 5 year follow-up period in HIV-1 + patients who have a CD4+ cell count above or equal to 300 cells/mm3. The first patient was enrolled in USA on 13 March 2000 and the randomisation was closed with the enrollment of patient no. 4150 on 31 May 2003.
CHIP is one of four regional trial centers and is responsible for clinics in Scandinavia, Germany,
Spain, Portugal, Belgium, Poland and Austria. ESPRIT is an international collaboration between 23 countries world-wide.
The ESPRIT002:STALWART trial will compare the effects of subcutaneous (SC) recombinant interleukin-2 (rIL-2) administered with and without concomitant pericycle highly active antiretroviral therapy (HAART) to no therapy on CD4+ T lymphocyte count in patients with HIV-1 infection and CD4+ T lymphocyte count >300 cells/mm3. Pericycle HAART is HAART given only for a few days before, during and after each 5-days IL-2 cycle.
CHIP is one of four regional trial centres in STALWART. CHIP is responsible for sites in Germany, Poland, Portugal and Spain. This study will enrol about 480 people around the world of which 132 are expected to come from these countries. The study will last about 2 years.
The SILCAAT study will compare the effects of subcutaneous recombinant interleukin-2 (SC rIL-2) and no SC rIL-2 on disease progression and death over an average follow-up period of 6-7 years period in patients with HIV-1 + patients who have a CD4+ cell count between 50 and 299 cells/mm3 and a viral load <10,000 copies/mL
CHIP is one of four regional trial centers. The Copenhagen Regional Center is responsible for centers in Germany, Spain and Belgium (418 patients have been enrolled from these countries).
Coordination of national randomised trials
The PASS study (The Procalcitonin and Survival Study)
The PASS Study is a randomized, single-blinded, multicenter trial to investigate if clinical management guided by daily standardized Procalcitonin measurements
Updated: 02 Dec 2008